Published in BMC Cardiovasc Disord on October 24, 2013
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74
Natriuretic peptides. N Engl J Med (1998) 6.04
Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation (2004) 3.05
Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res (2002) 2.98
N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol (2003) 2.36
Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem (1992) 2.34
Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol (2006) 2.29
Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation (1998) 2.17
Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J (2007) 1.99
Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res (2005) 1.79
Increased cardiac BNP expression associated with myocardial ischemia. FASEB J (2003) 1.78
Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur Heart J (2004) 1.71
Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation (2006) 1.69
Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol (2006) 1.64
Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation (2001) 1.59
Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep (2010) 1.37
Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT1-MMP). FEBS Lett (1996) 1.37
Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail (2004) 1.35
TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. Circ Res (2010) 1.32
Expression of vascular endothelial growth factor in patients with acute myocardial infarction. J Am Coll Cardiol (2000) 1.28
Acute myocardial hypoxia increases BNP gene expression. FASEB J (2004) 1.12
Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation (2003) 1.12
The late open artery hypothesis--a decade later. Am Heart J (2001) 0.99
High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol (1998) 0.97
Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure. Am J Cardiol (2011) 0.96
Circulating level of gelatinase activity predicts ventricular remodeling in patients with acute myocardial infarction. Int J Cardiol (2005) 0.93
Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function. J Card Fail (2007) 0.87
Early Activation of Metalloproteinases after Experimental Myocardial Infarction Occurs in Infarct and Non-infarct Zones. Cardiovasc Pathol (2015) 0.82
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74
Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med (2009) 7.71
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med (2006) 3.56
Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension (2011) 2.68
Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J (2009) 2.68
[Apical ballooning syndrome in a 57-year-old woman during premedication for general anaesthesia]. Kardiol Pol (2006) 2.67
Resistance to oral antiplatelet drugs--a Position Paper of the Working Group on antiplatelet drug resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society. Kardiol Pol (2008) 2.63
Part 10: acute coronary syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation (2010) 2.62
Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation (2008) 2.59
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation (2010) 2.49
Cardiopulmonary resuscitation quality: [corrected] improving cardiac resuscitation outcomes both inside and outside the hospital: a consensus statement from the American Heart Association. Circulation (2013) 2.49
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2010) 2.41
L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA (2006) 2.24
Pulmonary artery catheterization in acute coronary syndromes: insights from the GUSTO IIb and GUSTO III trials. Am J Med (2005) 2.08
Navigating the crossroads of coronary artery disease and heart failure. Circulation (2006) 2.06
Regional differences in determining cardiovascular diseases as the cause of death in Poland: time for change. Kardiol Pol (2012) 2.06
Platelet activation and microvascular injury in patients with ST-segment elevation myocardial infarction. Kardiol Pol (2012) 2.05
Superior early diagnostic performance of a sensitive cardiac troponin assay as compared to a standard troponin test in the diagnosis of acute myocardial infarction. Kardiol Pol (2012) 2.03
OSACS score-a new simple tool for identifying high risk for Obstructive Sleep Apnea Syndrome based on clinical parameters. Anatol J Cardiol (2014) 1.99
A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. J Am Coll Cardiol (2002) 1.98
Clinical, biochemical and genetical resistance to clopidogrel in a patient with the recurrent coronary stent thrombosis--a case report and review of the literature. Int J Cardiol (2005) 1.95
Efficacy of multi-electrode duty-cycled radiofrequency ablation in patients with paroxysmal and persistent atrial fibrillation. Cardiol J (2013) 1.93
Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr (2005) 1.84
The role of cardiac registries in evidence-based medicine. Eur Heart J (2010) 1.83
Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol (2004) 1.77
Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol (2005) 1.71
Enrollment of women in National Heart, Lung, and Blood Institute-funded cardiovascular randomized controlled trials fails to meet current federal mandates for inclusion. J Am Coll Cardiol (2008) 1.68
Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina. J Am Coll Cardiol (2002) 1.67
Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. Chest (2007) 1.66
International participation in cardiovascular randomized controlled trials sponsored by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol (2011) 1.65
Prevalence and characteristics of coronary anomalies originating from the opposite sinus of Valsalva in 8,522 patients referred for coronary computed tomography angiography. Am J Cardiol (2013) 1.64
Predictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction: Results from the OAT (Occluded Artery Trial) study. JACC Cardiovasc Interv (2008) 1.63
Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone. Am J Cardiol (2002) 1.60
Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum. J Clin Lipidol (2013) 1.58
Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial. Eur Heart J (2004) 1.58
Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA (2013) 1.54
Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes. Kardiol Pol (2009) 1.54
Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial. Catheter Cardiovasc Interv (2009) 1.54
Early abciximab use in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention improves long-term outcome. Data from EUROTRANSFER Registry. Kardiol Pol (2010) 1.54
Systemic blood coagulation activation in acute coronary syndromes. Blood (2008) 1.53
The size does not matter - the presence of microvascular obstruction but not its extent corresponds to larger infarct size in reperfused STEMI. Eur J Radiol (2011) 1.51
TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. Eur Heart J (2007) 1.50
Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns. Acad Emerg Med (2005) 1.49
Do bisphosphonates slow the progression of aortic stenosis? J Am Coll Cardiol (2012) 1.48
Leptin in acute myocardial infarction and period of convalescence in patients with type 2 diabetes mellitus. Kardiol Pol (2010) 1.47
Cognitive disorders in elderly patients with permanent atrial fibrillation. Kardiol Pol (2009) 1.46
Transcatheter aortic valve implantation using transfemoral/transsubclavian or transapical approach: 30-day follow-up of the initial 30 patients. Kardiol Pol (2011) 1.46
Availability of automated external defibrillators in the city of Warsaw - status for May 2009. Kardiol Pol (2010) 1.45
Plasma adiponectin levels in acute myocardial infarction and during the postinfarction recovery period in patients with type 2 diabetes mellitus. Kardiol Pol (2011) 1.44
Efficacy of catheter ablation in patients with an electrical storm. Kardiol Pol (2011) 1.43
Comparison of on-admission ST-segment elevation tako-tsubo patients and myocardial infarction women: in-hospital course and long-term follow-up. Kardiol Pol (2012) 1.43
Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism. Kardiol Pol (2012) 1.43
The effects of left ventricular diastolic function on natriuretic peptide levels after cardioversion of atrial fibrillation. Kardiol Pol (2009) 1.42
Magnitude and consequences of missing the acute infarct-related circumflex artery. Am Heart J (2009) 1.42
What has changed in the treatment of ST-segment elevation myocardial infarction in Poland in 2003-2009? Data from the Polish Registry of Acute Coronary Syndromes (PL-ACS). Kardiol Pol (2011) 1.42
CHA2DS2-VASc and R2CHA2DS2-VASc scores have predictive value in patients with acute coronary syndromes. Pol Arch Med Wewn (2015) 1.41
Does contrast agent injection during trans-catheter aortic valve implantation negatively affect kidney function? Kardiol Pol (2011) 1.41
Prevalence of classical risk factors in Polish women with premature coronary artery disease. Kardiol Pol (2010) 1.41
Access to selected diagnostic procedures in the management of heart failure patients in Poland - POLKARD 2005. Kardiol Pol (2010) 1.41
Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality. Eur Heart J (2009) 1.41
IgG, IgM and inflammatory markers serum concentration in patients with acute coronary syndrome: a pilot study. Kardiol Pol (2012) 1.41
Efficacy and tolerability of oral propafenone versus quinidine in the treatment of recent onset atrial fibrillation: A randomized, prospective study. Cardiol J (2009) 1.41
Status of women in cardiovascular clinical trials. Arterioscler Thromb Vasc Biol (2009) 1.41
Clinical significance of radiologic characterizations in COPD. COPD (2009) 1.41
No correlation between atrial natriuretic peptide concentrations and echocardiographic measurements of left atrial size or left ventricular size and function in patients with persistent atrial fibrillation. Pacing Clin Electrophysiol (2005) 1.41
Prognostic value of novel biomarkers compared with detailed biochemical evaluation in patients with heart failure. Pol Arch Med Wewn (2015) 1.41
Cardiogenic shock in the setting of severe aortic stenosis: role of intra-aortic balloon pump support. Heart (2010) 1.40
Abrasions of the outer silicone insulation of endocardial leads in their intracardiac part: a new mechanism of lead-dependent endocarditis. Europace (2012) 1.40
Inflammatory response and postoperative kidney failure in patients with diabetes type 2 or impaired glucose tolerance undergoing heart valve surgery. Kardiol Pol (2010) 1.40
Options for managing severe aortic stenosis: a case-based review. Cleve Clin J Med (2013) 1.40
Functionally driven complete vs incomplete revascularisation in multivessel coronary artery disease--long-term results from a large cohort. Kardiol Pol (2010) 1.40
Over 10 years with an implantable cardioverter-defibrillator - a long term follow-up of 60 patients. Kardiol Pol (2010) 1.40
Atrial natriuretic peptide level after cardioversion of chronic atrial fibrillation. Int J Cardiol (2002) 1.40
Ischaemia modified albumin in patients with acute coronary syndrome and negative cardiac troponin I. Scand J Clin Lab Invest (2013) 1.39
'Syringe-in-the-pocket'--a new approach to the outpatient thromboembolic prophylaxis of recurrent atrial fibrillation. Cardiology (2007) 1.39
Impact of infarct related artery patency after early abciximab administration on one-year mortality in patients with ST-segment elevation myocardial infarction (data from the EUROTRANSFER Registry). Kardiol Pol (2012) 1.39
Effects of exercise testing on natriuretic peptide secretion in patients with atrial fibrillation. Kardiol Pol (2009) 1.39
Transcatheter aortic valve implantation using direct aortic access: first procedures in Poland. Kardiol Pol (2012) 1.39
Evaluation of safety and the success rate of cryoballoon ablation of the pulmonary vein ostia in patients with atrial fibrillation--a preliminary report. Kardiol Pol (2010) 1.39
Can thromboembolic risk be associated with erectile dysfunction in atrial fibrillation patients? Cardiol J (2015) 1.39
Osborn waves during therapeutic hypothermia in a young ST-ACS patient after out-of-hospital cardiac arrest. Kardiol Pol (2013) 1.39
Age-related gap in the management of heart failure patients. The National Project of Prevention and Treatment of Cardiovascular Diseases--POLKARD. Cardiol J (2012) 1.39
Anti-ischaemic response to sublingual nitroglycerin during oral administration of isosorbide dinitrate in patients with stable angina pectoris: when does cross-tolerance occur? Cardiovasc Drugs Ther (2004) 1.39
[Conduction disturbances and permanent cardiac pacing after transcatheter implantation of the CoreValve aortic bioprosthesis: initial single centre experience]. Kardiol Pol (2012) 1.39
The role of B-type natriuretic peptide in the evaluation of left atrioventricular valve regurgitation following surgical repair of partial atrioventricular canal. Kardiol Pol (2012) 1.38
Factor XIa and tissue factor activity in patients with coronary artery disease. Thromb Haemost (2008) 1.27
Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med (2005) 1.24